IL-5 antibody, antigen binding fragment thereof, and medical application therefor
Provided are an IL-5 antibody, an antigen binding fragment thereof, and a medical application therefor. The present invention comprises a mouse-derived antibody containing an IL-5 antibody CDR region, a chimeric antibody, a humanized antibody, and a pharmaceutical composition comprising said IL-5 antibody and said antigen binding fragment thereof, as well as the use of the pharmaceutical composition as a drug.
1. A monoclonal antibody or antigen-binding fragment thereof specifically binding to human IL-5, wherein the monoclonal antibody comprises a heavy chain variable region and a light chain variable region, wherein,
(i) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 region as set forth in amino acid sequences of SEQ ID NOs: 16-18; and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 region as set forth in amino acid sequences of SEQ ID NOs: 19-21; or
(ii) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 region as set forth in amino acid sequences of SEQ ID NOs: 22-24; and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 region as set forth in amino acid sequences of SEQ ID NOs: 25-27; or
(iii) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 region as set forth in amino acid sequences of SEQ ID NOs: 28-30; and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 region as set forth in amino acid sequences of SEQ ID NOs: 31-33; or
(iv) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 region as set forth in amino acid sequences of SEQ ID NOs: 34-36; and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 region as set forth in amino acid sequences of SEQ ID NOs: 37-39; or
(v) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 region as set forth in amino acid sequences of SEQ ID NOs: 40-42; and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 region as set forth in amino acid sequences of SEQ ID NOs: 43-45; or
(vi) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 region as set forth in amino acid sequences of SEQ ID NOs: 34-36; and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 region as set forth in amino acid sequences of SEQ ID NOs: 37-39.
2. The monoclonal antibody or antigen-binding fragment thereof according to claim 1 , wherein the monoclonal antibody is a recombinant antibody selected from the group consisting of murine antibody, chimeric antibody, and humanized antibody.
3. The monoclonal antibody or antigen-binding fragment thereof according to claim 2 , wherein the humanized antibody comprises a heavy chain variable region of SEQ ID NO: 49, 57, 63, 69 or 75.
4. The monoclonal antibody or antigen-binding fragment thereof according to claim 3 , further comprising a back mutation, wherein the back mutation is selected from the group consisting of S49T, V93T and K98S, or a combination thereof on the heavy chain variable region of SEQ ID NO: 49, or the back mutation is selected from the group consisting of S49T, V93T and K98T, or a combination thereof on the heavy chain variable region of SEQ ID NO: 57, or the back mutation is selected from the group consisting of R38K, M48I , R67K, V68A, M70L, R72V, T74K and L83F, or a combination thereof on the heavy chain variable region of SEQ ID NO:63, or the back mutation is selected from the group consisting of F29I , R38K, V48I , R72A, T97F on the heavy chain variable region of SEQ ID NO:69, and N55V on CDR, or a combination thereof, or the back mutation is selected from the group consisting of R38K, M48I , R67K, V68A, R72A, T74K, M81L, L83F and D89E, or a combination thereof on the heavy chain variable region of SEQ ID NO:75.
5. The monoclonal antibody or antigen-binding fragment thereof according to claim 4 , wherein the humanized antibody comprises a heavy chain variable region of SEQ ID NO:50 or 51, or comprises a heavy chain variable region of SEQ ID NO: 58 or 59, or comprises a heavy chain variable region selected from any one of SEQ ID NO: 64, 65 and 66, or comprises a heavy chain variable region of SEQ ID NO:70 or 71, or comprises a heavy chain variable region selected from any one of SEQ ID NOs: 76 to 79.
6. The monoclonal antibody or antigen-binding fragment thereof according to claim 2 , wherein the humanized antibody comprises a light chain variable region of SEQ ID NO: 46, 54, 60, 67 or 72.
7. The monoclonal antibody or antigen-binding fragment thereof according to claim 6 , further comprising a back mutation, wherein the back mutation is selected from the group consisting of A43 S, L47V, G66R, T69S, F71Y and Y87F or a combination thereof on the light chain variable region of SEQ ID NO:46; or the back mutation is selected from the group consisting of A43S, L47M, F71Y and Y87F or a combination thereof on the light chain variable region of SEQ ID NO: 54; or the back mutation is selected from the group consisting of E1D, I2T, I57V, V84T and Y86F or a combination thereof on the light chain variable region of SEQ ID NO: 60; or the back mutation is selected from the group consisting of M4L, A42S, L45P and L46W or a combination thereof on the light chain variable region of SEQ ID NO: 67; or the back mutation is selected from the group consisting of A43S, I48V and F71Y or a combination thereof on the light chain variable region of SEQ ID NO:72.
8. The monoclonal antibody or antigen-binding fragment thereof according to claim 7 , wherein the humanized antibody comprises a light chain variable region of SEQ ID NO: 47 or 48; or comprises a light chain variable region of SEQ ID NO: 55 or 56; or comprises a light chain variable region of SEQ ID NO: 61 or 62; or comprises a light chain variable region of SEQ ID NO: 68; or comprises a light chain variable region of SEQ ID NO: 73 or 74.
9. The monoclonal antibody or antigen-binding fragment thereof according to claim 1 , wherein the humanized antibody comprises:
a heavy chain variable region selected from any one of SEQ ID NOs: 49-51 and a light chain variable region selected from any one of SEQ ID NOs: 46-48; or
a heavy chain variable region selected from any one of SEQ ID NOs: 57-59 and a light chain variable region selected from any one of SEQ ID NOs: 54-56; or
a heavy chain variable region selected from any one of SEQ ID NOs: 63-66 and a light chain variable region selected from any one of SEQ ID NOs: 60-62; or
a heavy chain variable region selected from any one of SEQ ID NOs: 69-71 and a light chain variable region selected from any one of SEQ ID NOs: 67-68; or
a heavy chain variable region selected from any one of SEQ ID NOs: 75-79 and a light chain variable region selected from any one of SEQ ID NOs: 72-74.
10. The monoclonal antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody is a full length antibody, and further comprises a human antibody constant region, and wherein the full-length antibody comprises a human antibody heavy chain constant region as set forth in SEQ ID NO: 52 and a human light chain constant region as set forth in SEQ ID NO:53.
11. The monoclonal antibody or antigen-binding fragment thereof according to claim 1 , wherein the antigen-binding fragment is selected from the group consisting of Fab, Fab′, F(ab′)2, single-chain antibody (scFv), dimerized V region (diabody), and disulfide-stabilized V region (dsFv).
12. A pharmaceutical composition comprising a therapeutically effective amount of the monoclonal antibody or antigen-binding fragment thereof according to claim 1 , and one or more pharmaceutically acceptable carriers, diluents, buffers or excipients.